Phase I / Dose Expansion Study of Enadenotucirev in Ovarian Cancer Patients

NCT02028117 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

38

Enrollment

INDUSTRY

Sponsor class

Conditions

Recurrent Platinum Resistant Ovarian Cancer

Interventions

BIOLOGICAL: Enadenotucirev

Sponsor

Akamis Bio